Epizyme, Inc.

This study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…

This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…

This program provides tazemetostat, an experimental drug taken as a pill twice daily, to adults with advanced epithelioid sarcoma—a rare cancer—who have no satisfactory alternative treatments. It is designed for people who cannot join other clinical studies or access the drug thr…

This was a phase 2 study testing the oral drug tazemetostat in adults with relapsed or refractory follicular lymphoma whose tumors lack an EZH2 gain-of-function mutation. The drug is already approved for this cancer, but researchers wanted to see how well it works in this specifi…